Floatz logo

Pegylated Recombinant Human Hyaluronidase Ph20

Pancreatic Adenocarcinoma Non-resectable

Scripps HealthPhase 2Dormant
D
29/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
14/ 100
Competitive Position
95/ 100

Competitive context

190 Active assets in the Pancreatic Adenocarcinoma Non-resectable cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Docetaxel
Bristol-Myers Squibb
Phase 2BBB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3BB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 4BB
Irinotecan
Ipsen
Phase 3BB

View all 50 →

Same molecule, other indications

Pegylated Recombinant Human Hyaluronidase Ph20 is also rated in:

pancreatic ductal adenocarcinomaDormant
D
Indicative ·
30 / 100
View asset →
pancreatic adenocarcinomaDormant
D
Indicative ·
29 / 100
View asset →
malignant pancreatic neoplasmDormant
D
Indicative ·
29 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →